DJIA 17,031.14 43.63 0.26%
NASDAQ 4,518.90 -48.70 -1.07%
S&P 500 1,984.13 -1.41 -0.07%
market minute promo

Sarepta Therapeutics (NASDAQ: SRPT)

22.72 -1.06 (-4.46%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

SRPT $22.72 -4.46%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $23.59
Previous Close $23.78
Daily Range $22.21 - $23.70
52-Week Range $12.12 - $55.61
Market Cap $929.8M
P/E Ratio -7.95
Dividend (Yield) $0.00 (0.0%)
Volume 1,034,930
Average Daily Volume 1,051,954
Current FY EPS -$3.60

Sector

Healthcare

Industry

Drugs

Sarepta Therapeutics (SRPT) Description

A biopharmaceutical company developing therapeutic products principally based on third-generation NEUGENE antisense technology. Website: http://www.sareptatherapeutics.com/

News & Commentary

George Soros Is Betting on This Risky Stock: Should You?

Sarepta Therapeutics is a clinical-stage biotechnology company seeking to gain approval for a potentially game-changing Duchenne muscular dystrophy drug called eteplirsen. Wall Street appears convinced that the drug is a winner, but scientists have been less optimistic. Here's why.

Ebola-Stricken Doc Receives Experimental Drug, But Which One?

Sarepta Therapeutics' (SRPT) CEO Chris Garabedian at Morgan Stanley Healthcare Conference (Transcrip

Sarepta Therapeutics' (SRPT) CEO Chris Garabedian at Morgan Stanley Healthcare Conference (Transcript)

Trade Ebola Stocks? Sure, But Don't Bet on Big Business Opportunity

Ebola Outbreak Strikes Africa: How We're Fighting Back

Multiple drugs and vaccines are in development.

4 Companies To Look At After WHO Ebola Consultation In Geneva

The Best Hedge Fund You've Never Heard Of and Its Top 5 Stock Picks

Sarepta Therapeutics Reports Wider Y/Y Loss, Revenues Miss - Analyst Blog

Sarepta Therapeutics Reports Wider Y/Y Loss, Revenues Miss - Analyst Blog

Biotechs That Might Benefit From Ebola

Today's Market: News Moving These Names

See More SRPT News...

SRPT's Top Competitors

SRPT $22.72 (-4.46%)
Current stock: SRPT
GILD $100.99 (-2.58%)
Current stock: GILD
CELG $89.46 (-2.25%)
Current stock: CELG
BIIB $320.12 (-1.01%)
Current stock: BIIB